InvestSMART

Halozyme Therapeutics (NASDAQ: HALO) - Share Price

Current share price for HALO : $107.180 0.18 (0.17%)+

Currency: USD ($)

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

HALO General Information +

NASDAQ Code HALO
Industry/Sector Biotechnology
Market Cap ($M) 12,164
HALO Share Price $107.180
Day High $108.140
Day Low $106.440
Last Close $107.000
HALO Share Price Movement $0.18 ( 0.17% )
Prices as at 3:46, 12 Sep 2026
+Security prices are at best end-of-day and are indicative only.

HALO Financial Summary

Operating Revenue Per Share Price to Operating revenue Price to free cash flow Earnings Yield PE Ratio Dividend Yield Forward Dividend Yield Forward Earnings Yield
$6.88 $15.58 $25.27 3.18% 31.43 n/a n/a 9.16

HALO Calendar of Events

Created Date Changed Date Event
24 March 2026 24 March 2026 Company Meeting

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.